How to appeal a UnitedHealthcare men's sexual health — trt + ed denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for men's sexual health — trt + ed

Cited policy: OptumRx Testosterone Replacement Therapy (Gels, Patches, Solutions) PA

Adult male with documented hypogonadism: ≥2 separate AM (before 10 a.m.) total-testosterone measurements <300 ng/dL (or <264 ng/dL by LC-MS/MS) AND specific symptoms (decreased libido, erectile dysfunction, fatigue, depressed mood, decreased lean body mass). Workup includes LH/FSH, prolactin, PSA (≥40 yr or risk factors), hematocrit, lipids. Excludes treatment for non-specific symptoms in eugonadal men. Reauth at 6 mo with response + monitoring labs (T trough, hematocrit ≤54%, PSA stable).

How UnitedHealthcare denies men's sexual health — trt + ed — and how to counter it

Where UnitedHealthcare pushes back: 1) Only one low T draw on file; 2) 'Age-related' — not covered; 3) CV risk concern; 4) Try generic cypionate first; 5) Prostate-cancer history disqualifies.

Counter-arguments that hold up: Cite both AM total-T draws + assay method (LC-MS/MS preferred) per AUA 2018 + Endocrine Society 2018. AUA 2018 explicitly supports treating age-associated/late-onset hypogonadism when threshold + symptoms met. TRAVERSE NEJM 2023 (Lincoff, 5246 men with CV risk) — primary 3-point MACE NON-INFERIOR vs placebo over ~3 yr; refuted older retrospective CV signals. Gel formulation justified when injection-averse, transfer-risk manageable (no young children/pregnant partner contact), or steady-state PK preferred. For prostate-cancer history: AUA 2018 individualizes (Loeb J Urol 2023, Khera J Urol 2015) — low-risk treated patients can be considered.

What UnitedHealthcare typically denies for men's sexual health — trt + ed

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For men's sexual health — trt + ed, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the men's sexual health — trt + ed treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Testosterone cypionate
• Testosterone enanthate
• Aveed (TU IM)
• Xyosted (TE SC)
• Testosterone gel
• Axiron (T solution)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.